|
Morris Rosenberg joined Seattle Genetics in July 2001. Prior to joining the company, he was with Eli Lilly & Company (1998-2001), Biogen Incorporated (1990-1998) and Invitron Corporation (1987-1990). Dr. Rosenberg received a D.Sc. in Chemical Engineering, an M.S. and B.S. in Chemical Engineering, and a B.A. in Biology from Washington University in St. Louis, Missouri. While at Biogen he participated in the development of the manufacturing process for the multiple sclerosis treatment Avonex. Most recently at Eli Lilly, as Head of Cell Culture and Fermentation Development, Dr. Rosenberg led efforts in the development of several cell culture processes including for the sepsis therapeutic Xigris.
| 